Navigation Links
Nautilus Neurosciences Announces New Patent Issued

BEDMINSTER, N.J., Feb. 1, 2012 /PRNewswire/ -- Nautilus Neurosciences, Inc., a neurology-focused specialty pharmaceutical company headquartered in Bedminster, New Jersey, announced today that United States Patent and Trademark Office has issued U.S. Patent 8,097,651 entitled "Diclofenac formulations and methods of use." This patent relates to methods and formulations for treating migraine. Additionally, methods are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting. The patent provides additional protection for Cambia™, Nautilus' marketed product for the treatment of migraine through June 2026. This patent was licensed to Nautilus for Cambia™ in the North American markets by the Swiss company APR Applied Pharma Research, and is now listed in the FDA's Orange Book.

This coverage is in addition to that provided by U.S. Patent Nos. 7,759,394; 7,482,377; and 6,974,595.


Nautilus' lead product, CAMBIA™, is a novel treatment for acute migraine in adults. CAMBIA is the only prescription non-steroidal anti-inflammatory drug (NSAID) available for the acute treatment of migraine. Engineered using Dynamic Buffering Technology (DBT), CAMBIA is specifically designed for fast, effective relief from the symptoms of migraine. Designed to treat the underlying pathophysiology of migraine, Cambia reaches peak blood levels within 15 minutes and has been proven to provide equally as rapid relief in migraine. The FDA approval of CAMBIA was based on two Phase 3 placebo-controlled trials showing that CAMBIA was superior to placebo in all four FDA-mandated co-primary end points for migraine -- pain, nausea, photophobia and phonophobia. Both studies also showed that reduction in pain intensity was significantly greater in the CAMBIA group than in the placebo group as early as 15 minutes following treatment, and headache response rates were superior to placebo for up to 24 hours.

Nautilus Neurosciences, Inc.

Nautilus Neurosciences is a neurology-focused specialty pharmaceutical company committed to providing the health care community with medically relevant products and services that directly benefit those affected by neurologic disorders. Nautilus is sponsored by Tailwind Capital and Galen Partners.

William Maichle
Chief Executive Officer
Nautilus Neurosciences, Inc.



SOURCE Nautilus Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nautilus Neurosciences and Tribute Pharmaceuticals Announce Exclusive Canadian License for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine
2. Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Womens Health Market
3. Intellect Neurosciences, Inc. to Present at BIO Asia International Conference
4. Intellect Neurosciences Files Appeal in Europe in Response to Opposition Proceedings Instituted by Elan Pharmaceuticals and Wyeth/Pfizer
5. Intellect Neurosciences, Inc. to Present at OneMedForum
6. Intellect Neurosciences Obtains Two New Patents in Japan for Its Alzheimers Immunotherapy Programs
7. Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimers Patent Application
8. Intellect Neurosciences Announces Its New CONJUMAB-A Platform Technology for Novel Treatments of Alzheimers Disease and Other Proteinopathies
9. Intellect Neurosciences Issues Letter to Shareholders
10. Intellect Neurosciences CEO to be Featured on Wall Street Reporter
11. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
Post Your Comments:
(Date:9/19/2017)... 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, ... three leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has ...
(Date:9/18/2017)... R.I. , Sept. 18, 2017 /PRNewswire/ ... the fields of bioinformatics and immune engineering, ... a protective avian influenza A (H7N9) vaccine. ... distantly related to seasonal influenza and presents ... rely on prior exposure to be effective. ...
(Date:9/12/2017)... 12, 2017  Consumer reviews on the independent review site ... number one company for hearing aids, ranking it higher than ... ... by Consumers For Hearing Aids ... is an online store that provides high performance, state-of-the-art, German-engineered hearing ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... Lori R. Somekh, founder of the Law Office of ... elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office remain ... to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... annual Holly Day Market. Featuring a collection of specialty vendors and unique items from ... of personalized and quality-focused health and wellness services offered by the VNA. The ...
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
Breaking Medicine News(10 mins):